The researchers found that in ovarian cancer cells with ARID1A mutation, PIK3IP1, a direct target gene of ARID1A and EZH2, was up-regulated after EZH2 was inhibited, leading to cell death by inhibiting the PI3K-AKT signaling pathway. The gene discussed is ARID1A; the disease is ovarian cancer.